Zobrazeno 1 - 10
of 15
pro vyhledávání: '"MA Navarro Dávila"'
Autor:
C Fraile Clemente, M Vera Cabrera, A Ferrer Machín, E Tévar Alfonso, J Merino Alonso, R Mesa Expósito, MA Navarro Dávila
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background Hospital malnutrition is a serious health problem with a high prevalence among hospitalised patients, which leads to the use of parenteral nutrition (NP). It should be noted that this artificial technique involves a large number of complic
Autor:
F. Pérez Hernández, R Mesa Expósito, I González García, Mdp Díaz Ruiz, E Tevar Afonso, M Suarez Gonzalez, FJ Merino Alonso, AM Gonzalez Rodriguez, CL Diaz Diaz, MA Navarro Dávila
Publikováno v:
Section 5: Patient Safety and Quality Assurance.
Background Obeticholic acid (OCA) is a synthetically modified bile acid that is used to treat a rare disease, the primary biliary cholangitis (PBC). OCA has been recently used in combination with ursodeoxycholic acid (UDCA) in adults who have not res
Autor:
A Ferrer Machín, I González García, FJ Merino Alonso, L Díaz Díaz, MA Ocaña Gomez, R Mesa Expósito, JA Montero Delgado, E Tévar Alfonso, MC Jordán de Luna, M Vera Cabrera, MA Navarro Dávila
Publikováno v:
Section 3: Production and Compounding.
Background Professional use of web 2.0 digital tools is increasing recently in the hospital pharmacy field. Symbaloo ( www. symbaloo.com ) is a free web-based tool that allows users to create a virtual desk to organise key information sources (links
Autor:
S Hernández Rojas, MM Viña Romero, F Gutiérrez Nicolás, J Merino Alonso, E Ramos Santana, MA Navarro Dávila, S. Ramos Linares
Publikováno v:
Eur J Hosp Pharm
Background Melanoma is the cutaneous tumour with the highest mortality. BRAF inhibitors are indicated for patients with metastatic melanoma and are part of the first-line treatment of this disease. Purpose To describe the clinical course of a patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f67af1fa4f0fb3025fe01f32345d578f
https://europepmc.org/articles/PMC7535375/
https://europepmc.org/articles/PMC7535375/
Autor:
I Plasencia García, FJ Merino Alonso, A Montero Delgado, E Ramos Santana, JA Leon Gil, S Hernández Rojas, C Fraile Clemente, MA Navarro Dávila, A Ferrer Machín, M Vera Cabrera, K Viñas Romero
Publikováno v:
Eur J Hosp Pharm
Background Hazardous drugs (MPs) are defined as the drugs that cause carcinogenicity, teratogenicity, reproductive toxicity, low-dose organ toxicity, genotoxicity, and new drugs with structure profiles and toxicity similar to existing drugs that were
Autor:
E Tévar Alfonso, E Ramos Santana, J Merino Alonso, MA Ocaña Gomez, I Plasencia García, M Suarez Gonzalez, MA Navarro Dávila
Publikováno v:
Clinical pharmacy.
Background Opioids are safe and effective drugs that improve the quality of life of patients with chronic pain. However, they require close monitoring and appropriate training. Pain specialists consider that pain often has a mixed origin that require
Autor:
I Plasencia García, MA Ocaña Gomez, MA Navarro Dávila, J Merino Alonso, M Suarez Gonzalez, JA Morales Barrios, David Sanchez Montero
Publikováno v:
Patient safety and risk management.
Background In 2014, we participated in the study EMOPEM through observation of drug administration errors. Purpose To describe the corrective measures implemented after participating in the EMOPEM project. Material and methods The study was conducted
Autor:
C Fraile Clemente, E Gómez Melini, MA Navarro Dávila, M Suarez Gonzalez, JA Morales Barrios, C Romero Delgado, J Merino Alonso, E Ramos Santana, T Betancor García, A Montero Delgado
Publikováno v:
European Journal of Hospital Pharmacy. 23:A125.2-A126
Background Atypical haemolytic uraemic syndrome (aHUS) is a severe life threatening disease with progression to end stage renal disease. Eculizumab, a humanised anti-C5 monoclonal antibody targeting the activated complement pathway, has been introduc
Autor:
MA Ocaña Gomez, I Plasencia García, M Suarez Gonzalez, JA Morales Barrios, A. de León Gil, E Tévar Alfonso, EG Fernández López, T Betancor García, MA Navarro Dávila, J Merino Alonso
Publikováno v:
European Journal of Hospital Pharmacy. 23:A123.1-A123
Background There are various types of botulinum toxin type A. There is no defined relationship in the equivalent power between them. Purpose To analyse botulinum toxint type A (Dysport 500 U and Botox 50–100 U) usage for different indications, and
Autor:
E Marques Guell, J Merino Alonso, EG Fernández López, C Fraile Clemente, I Plasencia García, MA Ocaña Gomez, JA Morales Barrios, MA Navarro Dávila, R Jurado López
Publikováno v:
European Journal of Hospital Pharmacy. 22:A40.2-A40
Background The clinical pharmacist’s main functions in parenteral nutrition (PN) are to ensure the appropriate assessment and monitoring of nutritional support according to the type of illness and the patient’s condition and to verify the quality